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TrastuzumabAbstract The blockage of cancer cell growth and division is the prime objective in clinical cancer
therapy both at early stages and for inhibition of minimal residual disease and relapse. The failure
of conventional therapies in treating breast cancer (BC) has prompted dissection of signalling path-
ways involved in BC cell growth and characterisation of cellular receptors. Speciﬁc sets of mem-
brane-bound receptors promote disarrayed self-renewal of BC stem cells and deregulated BC cell
proliferation. Individual blockage of each receptor promotes only incomplete inhibition of BC cell
growth and partial regression of metastasis. Such monotherapies are based on either chemotherapy
or monoclonal antibodies. However, they do not provide long-lasting beneﬁts and are further com-
promised by increasing resistance the cancer cells acquire against therapeutic agents, by their eva-
sion of receptor blockage and by adoption of alternative growth routes that are induced by cross-
talks between key receptors. On the other hand, dual targeting approaches, including receptor
blockage combined with chemotherapy, produce prolonged overall survival but, nevertheless, com-
plicate treatment by inducing side effects. Based on the complex nature of BC, combined targeted
strategies that potentially confer maximum coverage for treatment cannot be effective without over-
coming drug resistance initiated and further induced by inter-receptor communications. This
implies that a comprehensive strategy based on concomitant inhibition of key receptors could pro-
vide an ultimate solution for effective treatment of aggressive types of BC. Such a strategy would
likely be capable of targeting breast tumour cells and BC stem cells alike eventually forcing the can-
cer to regress.
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Breast cancer (BC) originates from the epithelial cells of the
breast tissue that line the terminal duct lobular unit [1]. Cancer
cells classiﬁed as in situ or non-invasive are the ones that re-
main within the basement membrane of the elements of the ter-
minal duct lobular unit and the draining duct. In an invasive
BC, on the other hand, there is dissemination of cancer cells
outside the basement membrane of the ducts and lobules into
the surrounding adjacent normal tissue [1].
More than 180,000 new cases of BC were diagnosed in 2008
in the United States alone [2]. Over 40,000 of these diagnosed
cases resulted in death, mostly in women [3]. In fact, BC in wo-
men is the most commonly diagnosed cancer that accounts for
26% of all new cancer cases [3].
Receptor signalling
A number of membrane-bound and intracellular receptors have
been identiﬁed in BC that promote cell proliferation and
growth signalling and so contribute to generation and progres-
sion of BC [4]. These growth signalling pathways either act gen-
erally, such as mitogen-activated protein kinase (MAPK),
phospholipase C (PLC)-c and PI3K/Akt [5], or are comprised
of molecules speciﬁc to stem cells and support their self-renewal
and/or differentiation, such as PTEN (Phosphatase and tensin
homolog), Wnt/b-catenin, [6]. The pathways are interconnected
and their signalling can be promoted by induction of, and
cross-talks between key BC cell receptors described below:
1. HER2: HER2 belongs to the human epidermal growth factor
receptor/epidermal growth factor receptor (HER/EGF) fam-
ily of receptors [7] that, upon induction and autophosphoryla-
tion, lead to transcription of pro-survival genes [8]. In 20–30%
of BC tumours, HER2 is either ampliﬁed, overexpressed or
undergoes both events [7]. A strong correlation exists between
HER2 levels and carcinogenesis [9]. High levels of HER2
found in cancer cell membranes compared to thoseof normal
cells andHER2 expression in both primary tumours andmet-
astatic sites have made HER2 inhibitors important for BC
therapy [9]. HER2 overexpression also acts as a driving force
for increased self-renewal of BC stem cells (BCSCs) and pro-
liferation of their progenitors, changes that are translated to
enhanced mammosphere formation and malignancy [10].
2. ER: Oestrogen receptor is expressed in over 70% of breast
tumours [11]. ER forms a complex with the oestrogen hor-
mone that regulates the expression of pro-survival genes
[12]. ER co-activators include AmpliWed in Breast Cancer
1 (A1B1) or Steroid Receptor Co-activator1 (SRC1). Co-
repressors, on the other hand, are recruited upon tamoxi-
fen–ER interaction and inhibit the expression of pro-sur-
vival genes [13].
3. Ret: Rearranged during transfection (RET) is a tyrosine
kinase receptor speciﬁc for glial cell line-derived neurotrophic
factor (GDNF). GDNF interaction with its second receptor
GFRa1 induces Ret leading to GDNF/GFRa1/Ret complex
formation. This complex induces kinase activity of Ret intra-
cellular domain and promotes interaction with SRC
(Schmidt-Ruppin A-2) kinase, an event that links Ret to sev-
eral intracellular signalling pathways of cell growth andprolif-
eration (Fig. 1) [14].Receptor cross-talks
HER2, Ret and ER have developed routes for mutual commu-
nications that provide compensatory approaches for growth
and proliferation signals. Estroidal as an ER ligand induces
a signal transduction cascade that trans-activates HER2 via
SRC tyrosine kinase and the matrix metalloproteases MMP-
2 and MMP-9 (Fig. 1) [15]. ER and HER2 act in synergy to
promote aberrant breast tumour growth [16]. The Ret/GDNF
pathway, on the other hand, contributes to ER overexpression
(Fig. 1) [17], stability [18] and phosphorylation/activation [19].
Co-inhibition of Ret and tamoxifen further supports inhibition
of cell growth and proliferation (Fig. 2).
Hormone resistance
Hormone therapy is aimed at depriving tumour cells of oestro-
gen (using tamoxifen or fulvestrant) to outcompete the hor-
mone for receptor binding [11,20] and aromatase inhibitors
to block oestrogen production [19]. Breast tumours often pro-
gress to the stage of resistance to steroid hormones [20,21].
Cross-talks between upstream kinases and ER are to blame
for this so-called ‘endocrine resistance’ because these cross-
talks activate the ER receptor in the absence of oestrogen or
hypersensitise it to the residual hormone [12,22].
Trastuzumab resistance
Trastuzumab (TZMB) resistance is shaped via a range of intra-
cellular signalling pathways that are interconnected and share in
key effector molecules [23]. De novo (intrinsic) resistance to
TZMB results from genetic changes in receptor tyrosine kinases
(RTKs) and their downstream cellular pathways, whereas the
acquired formof the resistance is causedmainly by shaping com-
pensatory kinase signalling pathways alternative toHER2-med-
iated pathways. There are also genetic alterations as a source of
both de novo and acquired forms of resistance. Recent reports
point to SRC as the central node behind TZMB resistance
[24]. This and the remaining pathways involved in TZMB resis-
tance are thoroughly discussed in our recent review [23].
Hypothesis
We are hypothesising that the full co-inhibition of BC cell
growth and BCSC self-renewal can be achieved by completely
co-blocking the key receptors that promote signalling of growth
pathways. The three key receptors that constitute the basis of
our strategy include HER2, ER and Ret (Fig. 1), as outlined be-
low. Our hypothesis emphasises on concomitant inhibition of
these three receptors (Fig. 3). Primarily, established BC cell lines
that co-express all three receptors will be used to apply this co-
inhibition. Due to the importance of HER2 ampliﬁcation/over-
expression in BC malignancy, a cell line that both ampliﬁes and
overexpresses HER2will be selected. Besides, a number of other
TZMBcell lines that express only one or two of the receptorswill
be used as controls. We anticipate that such a comprehensive
blockage will ensure that all complementing or compensatory
alternatives to growth/proliferation pathways are rendered dead
end and disconnected from their ultimate targets. Therefore,
resistance against hormone therapy or TZMB treatment will
be overcome and therapeutic efﬁcacywill be accelerated (Fig. 2).
Figure 1 Receptor-based growth pathways in breast cancer. Key receptors are shown phosphorylated upon ligand binding, a chemical
change that triggers downstream growth and proliferation pathways. Individual action of receptors (straight line arrows) and receptor
crosstalks between receptors (dotted arrows) can be chased by numbers: (1) Her2 effects: on growth pathways and SRC molecule as well
Her2-RET cross-talks, (2) ER effects on growth pathways, cPLA phosphorylation leading to mitochondrial damage and apoptosis, as well
as ER-Her2 cross-talks, (3) Ret effects on growth pathways and Ret-Her2. All three pathways can induce expression of pro-survival genes
that support cell growth and proliferation and overcome apoptosis. For details of signaling pathways see the text. BCCM, breast cancer
cell membrane; MMP, matrix metalloproeinases; A1B1, ER co-activator; cPLA2, Cytosolic phospholipase; T, mitochondria; NC, nucleus.
Figure 2 The effect of receptor co-blockage on breast cancer cell growth. Three key receptors are shown blocked by their antagonists:
TZMB inhibits Her2 dimerization and subsequent phosphorylation/activation. TAM competes out ER ligands from binding the receptor
and so inhibits ER phosphorylation/activation. siRNA blocks Ret receptor expression and so its biological functions. As shown by blue
crosses, simultaneous blockage of all three receptors will affect key growth pathways and promote apoptosis in BC cells. TAM, tamoxifen;
TZMB, trastuzumab. See text for more details.
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Figure 3 Our hypothesis. The hypothesis will be tested using both breast cancer cell lines and animal models as outlined in the text.
Within the center of the hypothesis resides blockage of three key receptors: Her2, Ret and ER. This will be followed by comprehensive
evaluations of each blockage step. Alterations in gene expression, cell growth/proliferation and as mentioned in the text, protein
phosphorylation and activity will be tested. The data generated from these experiments will introduce the optimum procedure for ultimate
arrest of growth and proliferation. TAM, tamoxifen; TZMB, trastuzumab; WB, Western blot. See text for more details.
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1. Plan for receptor blockage: concomitant inhibition of BC
growth and BCSC self-renewal will be ensured by target-
ing HER2 with TZMB, blocking Ret using small interfer-
ing RNA (siRNA) or CD133 molecules and inhibiting
ER with tamoxifen or ER antagonists (Fig. 3). Two of
the receptors will be blocked at a time to examine if
and how the third receptor function in promoting cell
growth. Next, all three receptors will be inhibited by their
relevant antagonists (Fig. 2). TZMB will be added
directly to BC growth medium for HER2 inhibition. We
will also use a homemade lentivirus construct that co-har-
bours TZMB light and heavy chains with an IRES (inter-
nal ribosome entry site) in between. These vector stocks
have shown their speciﬁc interaction with Her2 and their
potency in reducing BC growth rate in our lab. A similar
lentivirus construct can also be made that carries short
hairpin RNA (shRNA) molecules or CD133 for targeting
Ret. Tamoxifen is a medication of choice for BC patients
and can be added to the growth medium of target BC
cells.2. Virus production and application: as described previously
[25], virus production will be monitored by an enzyme-
linked immunosorbent assay (ELISA) for HIV-1 capsid
protein p24 that works well for detection of mature recom-
binant lentiviruses. The expression levels of reporter ﬂuo-
rescent genes such as green ﬂuorescent protein (GFP) co-
expressed with candidate proteins measurable by ﬂow
cytometry or real-time (RT) polymerase chain reaction
(PCR) can be relied upon to determine virus titre. High-
titre virus stocks produced from TZMB clones will be
applied directly to growing target BC cells. Lentiviruses
carrying either Ret shRNAs or CD133 coding sequence will
be used to transduce BC cell lines.
3. Changes in gene expression: these changes will be tested at
messenger RNA (mRNA) level by RT-PCR and at protein
level by immunocytochemistry orWestern blot analysis using
protein-speciﬁc antibodies. More importantly, changes over
time in expression levels will be monitored using real-time
PCR. Primarily, the key receptor Ret will be monitored to
clarify if and towhat extent it is down-regulated. The next step
will monitor changes in one receptor as a result of a second
and/or third receptor inhibition. This later step will answer
48 S. Shojaei, M. Gardanehthe question of cross-talks between receptors: do they really
interact with each other in the BC cell line under examination?
All the experimental steps at mRNA levels will be repeated at
protein levels too tomake sure data frommRNAanalyses will
match with those of the ultimate protein levels as a deﬁnitive
sign of gene expression.
4. Evaluation of growth signalling pathways: major pathways
involved in BC cell growth and proliferation will be tested
for their activity by examining the phosphorylation status
of key molecules shaping the pathways. The data from
these experiments will be used to determine how effective
our strategy will be in regulating growth mechanisms.
5. Changes in BC cell growth: this step will determine the impact
of blocking receptors individually and jointly on cell growth
and proliferation rate. MTT viability assay and other proce-
dures canbe applied for cell survivalmeasurement.Cell prolif-
eration will be monitored using methods for staining nucleus,
measuring DNA content as well as detecting mitochondrial
membrane potential.We predict a highly signiﬁcant reduction
in cell growth/proliferation rate upon inhibition of all three
receptors compared to when one or two of them will be
blockedat a time.These analyseswill tell uswhether andunder
what circumstances cell growth is being fully halted.
6. Changes in BCSC cell growth: Aldeﬂuor is a test that mea-
sures aldehyde dehydrogenase (ALDH) enzyme activity in
ALDH-expressing cells. The data produced byAldeﬂuor tests
will indicate BCSC survivability and will be used to examine
the effect of receptor blockage on BCSC growth rate.
7. Tests in animal models of BC: Animal models of BC will be
created by intravenous injection of methylnitrosourea
(50 mg kg1 body weight) to female Sprague-Dawley rats.
Breast tumours can then be detected 100–150 days after
injection [26]. TZMB and tamoxifen will be administered
orally while LV-shRNA molecules will be injected to
tumour mass directly. As an alternative approach, tumour
cells that have received the optimal combination of anti-
receptor compounds will be injected to mice. The initial
and most important analysis in vivo will include monitoring
tumour size compared to controls.Discussion and conclusion
BC growth and progression to its metastasising stages are pro-
moted by cell signalling pathways to induction of which key
intracellular and membrane-bound receptors actively partici-
pate. It is, therefore, conceivable that inhibition of these key
receptors at both gene expression and functional levels can put
a halt on BC cell growth. Such inhibitory measures have been
effective only partially, and resistance to antibody or hormone
therapy reﬂects insurmountable problems associated with
monotherapies. In this article, we hypothesised that the key
for solution of therapeutic resistance lies in the methodologies
applied for receptor co-blockage. We believe upon single sup-
pression of one or two receptors; BC cells will still have a chance
to evade blockage of the due signalling pathways by activating
alternative pathways. On the other hand, simultaneous co-sup-
pression of key receptors will ensure all possible pathways lead-
ing to cell growth and proliferation remain inactivated
disallowing the cell from growing further. Ret, ER and HER2
all play active roles in BC cell and BCSC growth and prolifera-
tion. Our hypothesis indicates that the concomitant suppressionof these key receptors will prevent cell growth genes from being
activated and so will guarantee fully blocked growth of ER+/
HER2+ BC cells as long as receptor suppression is in place.
Overview Box
First Question: What do we already know about the
subject?
(BC) cells and BC stem cells express deﬁned receptors
that play key roles in tumorigenesis. The blockage of each
of these key receptors has shown to exert tangible impacts
on breast tumour growth and progression. However,
cross-talks between the receptors pave the ground for
alternative routes for drug resistance and tumour cell
growth. Such receptor interplays accelerate resistance to
hormone and antibody therapies in BC.
Second Question: What does your proposed theory add to
the current knowledge available, and what beneﬁts does it have?
We assume that individually blocking key receptors is
not a viable therapeutic option for ER+/HER2+ cases
BC because the effects of such separate blockages readily
can be neutralised by receptor cross-talks. Therefore, we
hypothesise a more comprehensive strategy for simulta-
neous inhibition of at least three key receptors that are
determinant of BC tumourgenicity.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
To the best of our knowledge, concomitant blockage
of the three key receptors in BC has not been reported
so far and, if applied, can be readily tested both in culture
dish and in animal models of the disease. Novel tests
would be to examine changes, upon receptor co-blockage,
in the activity of growth pathways, in the ability of BC
cells and BC stem cells in forming mammographs and in
tumour sizes in animal models.
BC growth and progression to its metastasising stages
are promoted by cell signalling pathways to induction of
which key intracellular and membrane-bound receptors
actively participate. It is, therefore, conceivable that inhi-
bition of these key receptors at both gene expression and
functional levels can put a halt on BC cell growth. Such
inhibitory measures have been effective only partially,
and resistance to antibody or hormone therapy reﬂects
insurmountable problems associated with monotherapies.
In this article, we hypothesised that the key for solution of
therapeutic resistance lies in the methodologies applied for
receptor co-blockage. We believe upon single suppression
of one or two receptors; BC cells will still have a chance to
evade blockage of the due signalling pathways by activat-
ing alternative pathways. On the other hand, simultaneous
co-suppression of key receptors will ensure all possible
pathways leading to cell growth and proliferation remain
inactivated disallowing the cell from growing further.
Ret, ER and HER2 all play active roles in BC cell and
BCSC growth and proliferation. Our hypothesis indicates
that the concomitant suppression of these key receptors
will prevent cell growth genes from being activated and
so will guarantee fully blocked growth of ER+/HER2+
BC cells as long as receptor suppression is in place.
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